Fennec Pharmaceuticals Inc (NASDAQ:FENC - Free Report) - Analysts at HC Wainwright decreased their Q2 2024 EPS estimates for Fennec Pharmaceuticals in a research note issued to investors on Thursday, April 4th. HC Wainwright analyst R. Selvaraju now anticipates that the company will earn $0.01 per share for the quarter, down from their previous forecast of $0.04. HC Wainwright currently has a "Buy" rating and a $18.00 target price on the stock. The consensus estimate for Fennec Pharmaceuticals' current full-year earnings is $0.13 per share. HC Wainwright also issued estimates for Fennec Pharmaceuticals' Q4 2024 earnings at $0.16 EPS, FY2024 earnings at $0.23 EPS and Q3 2025 earnings at $0.12 EPS.
A number of other equities research analysts have also weighed in on the stock. Wedbush reaffirmed an "outperform" rating and set a $16.00 price target on shares of Fennec Pharmaceuticals in a report on Monday, March 18th. Craig Hallum raised their price target on shares of Fennec Pharmaceuticals from $17.00 to $18.00 and gave the company a "buy" rating in a report on Monday, March 18th.
Get Our Latest Analysis on Fennec Pharmaceuticals
Fennec Pharmaceuticals Price Performance
FENC traded down $0.22 during trading hours on Friday, reaching $10.69. 103,807 shares of the stock traded hands, compared to its average volume of 109,738. The firm's fifty day simple moving average is $10.01 and its two-hundred day simple moving average is $9.14. The company has a market cap of $289.06 million, a price-to-earnings ratio of -17.52 and a beta of 0.38. Fennec Pharmaceuticals has a fifty-two week low of $6.30 and a fifty-two week high of $11.92.
Insider Buying and Selling at Fennec Pharmaceuticals
In other Fennec Pharmaceuticals news, CFO Robert Andrade sold 13,975 shares of the stock in a transaction on Monday, March 25th. The shares were sold at an average price of $11.00, for a total transaction of $153,725.00. Following the transaction, the chief financial officer now directly owns 105,746 shares in the company, valued at approximately $1,163,206. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. In other Fennec Pharmaceuticals news, CFO Robert Andrade sold 13,975 shares of the stock in a transaction on Monday, March 25th. The shares were sold at an average price of $11.00, for a total transaction of $153,725.00. Following the transaction, the chief financial officer now directly owns 105,746 shares in the company, valued at approximately $1,163,206. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Rosty Raykov sold 40,584 shares of the firm's stock in a transaction dated Wednesday, April 3rd. The stock was sold at an average price of $10.78, for a total transaction of $437,495.52. Following the completion of the transaction, the chief executive officer now owns 276,054 shares in the company, valued at $2,975,862.12. The disclosure for this sale can be found here. Insiders have sold 100,973 shares of company stock worth $1,090,636 in the last ninety days. 11.25% of the stock is owned by insiders.
Institutional Inflows and Outflows
A number of large investors have recently modified their holdings of the business. Sonic GP LLC acquired a new stake in shares of Fennec Pharmaceuticals in the 4th quarter worth about $23,111,000. Vanguard Group Inc. increased its holdings in shares of Fennec Pharmaceuticals by 1,294.3% in the 4th quarter. Vanguard Group Inc. now owns 1,140,063 shares of the company's stock worth $12,792,000 after acquiring an additional 1,058,295 shares during the period. BlackRock Inc. increased its holdings in shares of Fennec Pharmaceuticals by 1,507.6% in the 2nd quarter. BlackRock Inc. now owns 830,119 shares of the company's stock worth $7,330,000 after acquiring an additional 778,481 shares during the period. AIGH Capital Management LLC increased its holdings in shares of Fennec Pharmaceuticals by 6.9% in the 3rd quarter. AIGH Capital Management LLC now owns 373,526 shares of the company's stock worth $2,805,000 after acquiring an additional 24,069 shares during the period. Finally, Gendell Jeffrey L increased its holdings in shares of Fennec Pharmaceuticals by 0.9% in the 3rd quarter. Gendell Jeffrey L now owns 285,992 shares of the company's stock worth $2,148,000 after acquiring an additional 2,579 shares during the period. 55.51% of the stock is currently owned by institutional investors.
Fennec Pharmaceuticals Company Profile
(
Get Free Report)
Fennec Pharmaceuticals Inc, a biopharmaceutical company, develops product candidates for use in the treatment of cancer in the United States. Its lead product candidate is the Sodium Thiosulfate, which has completed the Phase III clinical trial for the prevention of cisplatin induced hearing loss or ototoxicity in children.
Further Reading
Before you consider Fennec Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Fennec Pharmaceuticals wasn't on the list.
While Fennec Pharmaceuticals currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.
Get This Free Report
